KRAS and neoplasm: In this study, the ALK mutation group had higher edema/tumor ratio (5.66 ± 21.15) than KRAS (5.08 ± 8.70) and EGFR (2.38 ± 6.13) positive mutation groups, implicating worse survival in the ALK mutation group.